Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS

References

• Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115–126. doi:10.1056/NEJM199901143400207.
   PubMed Web of Science ®Google Scholar
• May AE, Seizer P, Gawaz M. Platelets: inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol 2008;28(3):5–10. doi:10.1161/ATVBAHA.107.158915
   PubMed Web of Science ®Google Scholar
• Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001;103(13):1718–1720. doi:10.1161/01.CIR.103.13.1718
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32(9):2045–2051. doi:10.1161/ATVBAHA.108.179705
   PubMed Web of Science ®Google Scholar
• Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J, Mehilli J, von Beckerath N, Schomig A, Kastrati A, et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost 2010;104(12):1193–1200.
   PubMedGoogle Scholar
• Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011;105(Suppl 1):S34–42. doi10.1160/THS10-11-0717.
   PubMedGoogle Scholar
• Garlichs CD, Eskafi S, Raaz D, Schmidt A, Ludwig J, Herrmann M, Klinghammer L, Daniel WG, Schmeisser A. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart (British Cardiac Society) 2001;86(6):649–655. doi:10.1136/heart.86.6.649
   PubMed Web of Science ®Google Scholar
• Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394(6689):200–203. doi:10.1038/28204
   PubMed Web of Science ®Google Scholar
• Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 2011;31(5):969–979. doi:10.1161/ATVBAHA.110.207415
   PubMed Web of Science ®Google Scholar
• Miyao Y, Yasue H, Ogawa H, Misumi I, Masuda T, Sakamoto T, Morita E. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J 1993;126(6):1299–1304. doi:10.1016/0002-8703(93)90526-F
   PubMed Web of Science ®Google Scholar
• Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003;107(3):398–404. doi:10.1161/01.CIR.0000052617.91920.FD
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001;104(19):2266–2268. doi:10.1161/hc4401.099447
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101(15):1767–1772. doi:10.1161/01.CIR.101.15.1767
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Schondorf T, Hanefeld M, Forst T. High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. J Diabetes Sci Technol 2010;4(3):706–716. doi:10.1177/193229681000400326
   PubMedGoogle Scholar
• Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377(12):1119–1131. doi:10.1056/NEJMoa1707914
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-Segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315. doi:10.1093/eurheartj/ehv320.
   PubMed Web of Science ®Google Scholar
• Winter MP, von Lewinski D, Wallner M, Prüller F, Kolesnik E, Hengstenberg C, Siller-Matula JM. Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study. Sci Rep 2019;1(1):8194. doi:10.1038/s41598-019-44673-7
   Google Scholar
• Hengstenberg C, Siller-Matula JM. Shedding light on long-term effects of early antiplatelet strategies after fibrinolytic treatment in STEMI. J Am Coll Cardiol 2019;73(22):2829–2831. doi:10.1016/j.jacc.2019.04.008
   PubMed Web of Science ®Google Scholar
• Eyileten C, Soplinska A, Pordzik J, Siller-Matula JM, Postuła M. Effectiveness of antiplatelet drugs under therapeutic hypothermia: a comprehensive review. Clin Pharmacol Ther 2019;106(5):993–1005. ahead of print. doi:10.1002/cpt.1492.
   PubMed Web of Science ®Google Scholar
• Komosa A, Lesiak M, Krasiński Z, Grygier M, Siniawski A, Skorupski W, Olasińska-Wiśniewska A, Pyda M, Araszkiewicz A, Mitkowski P, et al. Optimal timing of P2Y12 inhibitor loading in patients undergoing PCI: a meta-analysis. Thromb Haemost 2019;119(6):1000–1020. doi:10.1055/s-0039-1683421
   PubMed Web of Science ®Google Scholar
• Gasecka A, Konwerski M, Pordzik J, Soplińska A, Filipiak KJ, Siller-Matula JM, Postuła M. Switching between P2Y12 antagonists - From bench to bedside. Vascul Pharmacol 2019;115:1–12. doi:10.1016/j.vph.2019.01.003.
   PubMed Web of Science ®Google Scholar
• Niezgoda P, Sikora J, Barańska M, Sikora A, Buszko K, Siemińska E, Marszałł MP, Siller-Matula JM, Jilma B, Alexopoulos D, et al. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. Thromb Haemost 2017;117(4):718–726. doi:10.1160/TH16-08-0670
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32(23):2999–3054. doi:10.1093/eurheartj/ehr236
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, Huber K. Epa. response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv 2013;6(11):1111–1128. doi:10.1016/j.jcin.2013.06.011
   PubMed Web of Science ®Google Scholar
• Kubisa MJ, Jezewski MP, Gasecka A, Siller-Matula JM, Postuła M. Ticagrelor - toward more efficient platelet inhibition and beyond. Ther Clin Risk Manag 2018 Jan 17(14):129–140. doi10.2147/TCRM.S152369.
   Google Scholar
• Milanowski L, Rasul F, Gajda SN, Eyileten C, Siller-Matula J, Postula M. Genetic variability of SRC family kinases and its association with platelet hyperreactivity and clinical outcomes: a systematic review. Curr Pharm Des 2018;24(5):628–640. doi:10.2174/1381612824666171213105002
   PubMed Web of Science ®Google Scholar
• Schoergenhofer C, Hobl EL, Schellongowski P, Heinz G, Speidl WS, Siller-Matula JM, Schmid M, Sunder-Plaßmann R, Stimpfl T, Hackl M, et al. Clopidogrel in critically Ill patients. Clin Pharmacol Ther 2018;103(2):217–223. doi:10.1002/cpt.878
   PubMed Web of Science ®Google Scholar
• Schoergenhofer C, Hobl EL, Staudinger T, Speidl WS, Heinz G, Siller-Matula J, Zauner C, Reiter B, Kubica J, Jilma B. Prasugrel in critically ill patients. Thromb Haemost 2017;117(8):1582–1587. doi:10.1160/TH17-03-0154
   PubMed Web of Science ®Google Scholar
• Navarese EP, Kolodziejczak M, Winter MP, Alimohammadi A, Lang IM, Buffon A, Lip GY, Siller-Matula JM. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study. Int J Cardiol 2017;227:644–649. doi:10.1016/j.ijcard.2016.10.084.
   PubMed Web of Science ®Google Scholar
• Chen YG, Xu F, Zhang Y, Ji QS, Sun Y, Lu RJ, Li RJ. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J 2006;119(1):32–36. doi:10.1097/00029330-200601010-00006
   PubMed Web of Science ®Google Scholar
• Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG, Plow E, Topol EJ. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004;93(6):679–684. doi:10.1016/j.amjcard.2003.11.048
   PubMed Web of Science ®Google Scholar
• Rosiak M, Postula M, Kaplon-Cieslicka A, Kondracka A, Trzepla E, Czlonkowski A, Janicki PK, Filipiak KJ, Opolski G. Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: the AVOCADO study. Cardiol J 2013;20(5):545–551. doi:10.5603/CJ.2013.0045
   PubMed Web of Science ®Google Scholar
• Muller K, Aichele S, Herkommer M, Bigalke B, Stellos K, Htun P, Fateh-Moghadam S, May AE, Flather M, Gawaz M, et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 2010;213(1):256–262. doi:10.1016/j.atherosclerosis.2010.07.023
   PubMed Web of Science ®Google Scholar
• Husted S, Storey RF, Harrington RA, Emanuelsson H, Cannon CP. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol 2010;33(4):206–212. doi:10.1002/clc.20732
   PubMed Web of Science ®Google Scholar
• Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, Marre M, Steg PG, Gowda N, Gore JM. GRACE investigators. Implications of diabetes in patients with acute coronary syndromes. The global registry of acute coronary events. Arch Intern Med 2004;164:1457–1463. doi:10.1001/archinte.164.13.1457.
   PubMed Web of Science ®Google Scholar
• Guo R, Yang L, Mu L, Pan X, Qi F. Long-term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction. Exp Ther Med 2017;4(4):1578–1583. doi:10.3892/etm.2017.4156
   Google Scholar
• Eda S, Kaufmann J, Roos W, Pohl S. Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Anal 1998;12(3):137–144. doi:10.1002/(SICI)1098-2825(1998)12:3<137::AID-JCLA2>3.0.CO;2-6
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemos JTH 2010;8(2):351–359. doi:10.1111/j.1538-7836.2009.03699.x
   PubMed Web of Science ®Google Scholar
• Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, et al. Working group on on-treatment platelet R. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62(24):2261–2273. doi:10.1016/j.jacc.2013.07.101
   PubMed Web of Science ®Google Scholar
• Winter MP, Koziński M, Kubica J, Aradi D, Siller-Matula JM. Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej 2015;11(4):259–280. doi:10.5114/pwki.2015.55596
   PubMed Web of Science ®Google Scholar
• Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, Gurbel PA, Tantry U, Navarese EP, Siller-Matula JM. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Eur Heart J Cardiovasc Pharmacother 2017;3(4):221–234. doi:10.1093/ehjcvp/pvw044
   PubMed Web of Science ®Google Scholar
• Winter MP, Schneeweiss T, Cremer R, Biesinger B, Hengstenberg C, Prüller F, Wallner M, Kolesnik E, von Lewinski D, Lang IM, et al. Platelet reactivity patterns in patients treated with dual antiplatelet therapy. Eur J Clin Invest 2019;49(6):e13102. doi:10.1111/eci.13102
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Hintermeier A, Kastner J, Kreiner G, Maurer G, Kratochwil C, Lang IM, Delle-Karth G. Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor. Vascul Pharmacol 2016;79:6–10. doi:10.1016/j.vph.2016.01.003.
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Akca B, Neunteufl T, Maurer G, Lang IM, Kreiner G, Berger R, Delle-Karth G. Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. Platelets 2016;27(4):373–377. doi:10.3109/09537104.2015.1095874
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G, Gouya G, Ruzicka K, Podczeck-Schweighofer A, Christ G. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 2013;167(5):2018–2023. doi:10.1016/j.ijcard.2012.05.040
   PubMed Web of Science ®Google Scholar
• Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J, Mehilli J, von Beckerath N, Schömig A, Kastrati A, et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost 2010;104(12):1193–1200. doi:10.1160/TH10-05-0266
   PubMedGoogle Scholar
• Adatia K, Farag MF, Gue YX, Srinivasan M, Gorog DA. Relationship of platelet reactivity and inflammatory markers to recurrent adverse events in patients with ST-elevation myocardial infarction. Thromb Haemost 2019;119(11):1785–1794. doi:10.1055/s-0039-1695007
   PubMed Web of Science ®Google Scholar
• Tatarunas V, Kupstyte-Kristapone N, Zvikas V, Jakstas V, Zaliunas R, Lesauskaite V. Factors associated with platelet reactivity during dual antiplatelet therapy in patients with diabetes after acute coronary syndrome. Sci Rep 2020;10(1):1–8. doi:10.1038/s41598-020-59663-3
   PubMed Web of Science ®Google Scholar
• Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813(5):878–888. doi:10.1016/j.bbamcr.2011.01.034
   PubMed Web of Science ®Google Scholar
• Gori AM, Cesari F, Marcucci R, Giusti B, Paniccia R, Antonucci E, Gensini GF, Abbate R. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis 2009;202(1):255–262. doi:10.1016/j.atherosclerosis.2008.04.001
   PubMed Web of Science ®Google Scholar
• Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res 2016;118(1):145–156. doi:10.1161/CIRCRESAHA.115.306656
   PubMed Web of Science ®Google Scholar
• Cox AA, Sagot Y, Hedou G, Grek C, Wilkes T, Vinik AI, Ghatnekar G. Low-dose pulsatile interleukin-6 as a treatment option for diabetic peripheral neuropathy. Front Endocrinol (Lausanne) 2017;2(8):89. doi10.3389/fendo.2017.00089.
   Google Scholar
• Ferreira IA, Mocking AI, Feijge MA, Gorter G, van Haeften TW, Heemskerk JW, Akkerman JW. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006;26:417–422. doi:10.1161/01.ATV.0000199519.37089.a0.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Ramírez C, Costa MA, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006;48(2):298–304. doi:10.1016/j.jacc.2006.03.038
   PubMed Web of Science ®Google Scholar
• Schuette C, Steffens D, Witkowski M, Stellbaum C, Bobbert P, Schultheiss HP, Rauch U. The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study. Cardiovasc Diabetol 2015;14(1):15. doi:10.1186/s12933-015-0182-7
   PubMedGoogle Scholar
• Geisler T, Anders N, Paterok M, Langer H, Stellos K, Lindemann S, Herdeg C, May AE, Gawaz M. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007;30(2):372–374. doi:10.2337/dc06-1625
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Vogiatzi C, Stavrou K, Vlassopoulou N, Perperis A, Pentara I, Xanthopoulou I. Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study. Cardiovasc Diabetol 2015;14(1):68. doi:10.1186/s12933-015-0232-1
   PubMedGoogle Scholar
• Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, et al. Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. J Am Coll Cardiol 2016;67(10):1145–1154. doi:10.1016/j.jacc.2015.12.062
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109(23_suppl_1):III-39-III-43. doi:10.1161/01.CIR.0000131517.20177.5a
   Web of Science ®Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45(1):89–118. doi:10.1146/annurev.pharmtox.45.120403.095748
   PubMed Web of Science ®Google Scholar
• Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008;14(1):37–44. doi:10.1016/j.molmed.2007.11.004
   PubMed Web of Science ®Google Scholar